Intel Patents Biocompatible Coatings for Medical Devices

biocompatible-coatingsStarting at the beginning of January 2013, I started publishing what we call Companies We Follow over on IPWatchdog.com. The primary author of the series is Steven Brachmann, a freelance journalist who has covered the technology sector for years.

One of our goals is to come up with a representative set of companies that we could realistically profile from time to time in order to get a feel for what the company is working on in terms of research and development. For the most part, you know when you profile Apple that you will see a lot of mobile and wireless technologies and associated gadgets, our profiles of IBM always show that they are heavy into cloud computing and intelligence-based software systems (think Watson) and our AT&T profiles typically show a company that focuses on communications and multi-media technologies. Then there are companies like Qualcomm that work on a variety of diverse, cutting-edge technologies. But, for the most part, you know what types of innovations you are likely to find.

(more…)

Challenge To Intel Data Evaluation Patent Among Reexamination Requests Filed Week of 10/3/11

Here is the latest installment of Reexamination Requests from Scott Daniels, of Reexamination Alert and Practice Center Contributor…

Intel obtained a patent last year for a method for sifting through data on “a support vector machine” to obtain certain information.  The method appears to have diverse applications, including the identification of disease-causing genes.  A request for reexamination of Intel’s patent was filed last Monday (see ex parte Request No. (1)). Though PTO documents do not disclose the identity of the Requester, it might be Health Discovery Corporation which is now attempting to provoke an interference with the Intel patent.

IBM requested reexamination of an Acqis computer security patent (see inter partes Request No. (3)). Acqis won a judgment against IBM earlier this year for $12 million in damages and $18.5 million in costs after a jury verdict of infringement of three other patents.  On ThursdayIBM filed a declaratory judgment action against Acqis regarding the ‘814 patent. (more…)